• Explore /
  • Poster
  • / Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial.

Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial.

Abstract Poster

Authors

null

Joseph Tintelnot

University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Joseph Tintelnot , Alexander Stein , Lisa Paschold , Eray Goekkurt , Christoph Schultheiß , Peter C. Thuss-Patience , Sylvie Lorenzen , Thomas Jens Ettrich , Jorge Riera Knorrenschild , Lutz Jacobasch , Stefan Kubicka , Salah-Eddin Al-Batran , Anke C. Reinacher-Schick , Daniel Pink , Marianne Sinn , Udo Lindig , Axel Hinke , Susanna Hegewisch-Becker , Mascha Binder

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03409848

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4026)

DOI

10.1200/JCO.2023.41.16_suppl.4026

Abstract #

4026

Poster Bd #

348

Abstract Disclosures

Similar Posters

First Author: Kohei Shitara

First Author: Nataliya Volodymyrivna Uboha

First Author: Yelena Y. Janjigian

First Author: Sylvie Lorenzen